| European Case Law Identifier: | ECLI:EP:BA:1999:T031795.19990226 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 26 February 1999 | ||||||||
| Case number: | T 0317/95 | ||||||||
| Application number: | 88200397.3 | ||||||||
| IPC class: | A61K 33/24 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Compositions and their use for treating gastrointestinal disorders | ||||||||
| Applicant name: | The Procter & Gamble Company | ||||||||
| Opponent name: | 01: Glaxo Group Limited 02: SmithKline Beecham plc. |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Novelty and patentability under Article 52(4) EPC: (questionable) Inventive step: (no), obvious modification in relation to simplification and patient's compliance |
||||||||
| Catchwords: |
Use claims directed to the second medical use of two known drugs - treatment by concurrent administration differing from treatment in the prior art by the prescribed regimen (see reasons No. 4). |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t950317eu1.html
Date retrieved: 17 May 2021